Clareo Health | An Observational Study on Efficacy and Safety in Subjects Using Levemir® for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
7–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Any subject with Type 1 or Type 2 diabetes mellitus is eligible for the study, including newly-diagnosed subjects who have never received insulin or an insulin analogue before. The selection of the subjects will be at the discretion of the individual physician
You may not be if
Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit
Currently being treated with insulin detemir
Previously enrolled in this study
Hypersensitivity to insulin detemir or to any of the excipients
Pregnancy, breast-feeding, the intention to become pregnant or judged not to be using adequate contraceptive measures.
